Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of α-interferon

Biology of Blood and Marrow Transplantation

Volumn 2, Issue 1, 1996, Pages 31-36

  Faber, Laura M ^a   Van Luxemburg Heijs, Simone A P ^a   Rijnbeek, Marion ^a   Willemze, Roel ^a   Falkenburg, J H Frederik ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

interferon; Chronic myeloid leukemia; Cytotoxic T lymphocytes; Minor histocompatibility antigens

Indexed keywords

ALPHA INTERFERON; HLA ANTIGEN; MINOR HISTOCOMPATIBILITY ANTIGEN;

ALLOTRANSPLANTATION; ANIMAL; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIGEN PRESENTATION; BONE MARROW TRANSPLANTATION; CYTOTOXICITY, IMMUNOLOGIC; HLA ANTIGENS; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; MINOR HISTOCOMPATIBILITY ANTIGENS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0030073233     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Silver R: Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phase. Hematol Oncol Clin North Am 4:319, 1990.
2. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M: Chronic myelogenous leukemia: A concise update. Blood 82:691, 1993.
3. Talpaz M, Kantarjian H, Kurzrock R, Truillo JM, Gutterman JU: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 114:532, 1991.
4. McGlave P: Bone marrow transplants in chronic myelogenous leukemia: An overview of determinants of survival. Semin Hematol 27:23, 1990.
5. Champlin R: Bone marrow transplantation for chronic myelogenous leukemia. Curr Opin Oncol 2:258, 1990.
6. Gale RP, Champlin RE: How does bone marrow transplantation cure leukaemia? Lancet 2:28, 1984.
7. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic marrow grafts. N Engl J Med 300:1068, 1979.
8. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990.
9. Apperley JF, Mauro FR, Goldman JM, Gregory W, Arthur CK, Hows J, Arcese W, Papa G, Mandelli F, Wardle D, Gravett P, Franklin G, Bandini G, Ricci P, Tura S, Iacone A, Torlontano G, Heit W, Champlin R, Gale RP: Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: Importance of a graft-versus-leukaemia effect. Br J Haematol 69:239, 1988.
10. Kolb HJ, Mittermueller J, Clemm C, Holler C, Ledderose G, Brehm G, Heim M, Wilmanns W: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462, 1990.
11. Antin JH: Graft-versus-leukemia: No longer an epiphenomenon. Blood 8:2273, 1993.
12. Porter DL, Roth MS, McGarigle C, James RN, Ferrara JLM, Antin JH: Induction of graft-versus-host disease as immunotherapy for relapse chronic myeloid leukemia. N Engl J Med 330:100, 1994.
13. Faber LM, Van Luxemburg-Heijs SAP, Willemze R, Falkenburg JHF: Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283, 1992.
14. Falkenburg JHF, Goselink HM, van der Harst D, van Luxemburg-Heijs SAP, Kooy-Winkelaar YM, Faber LM, de Kroon JFEM, Brand A, Fibbe WE, Willemze R, Goulmy E: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 174:27, 1991.
15. Tanaka K, Yoshioka T, Bieberich C, Jay G: Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 6:359, 1988.
16. Mentzer SJ, Krensky AM, Burakoff SJ: Mapping functional epitopes of the human LFA-1 glycoprotein: Monoclonal antibody inhibition of NK and CTL effectors. Hum Immunol 17:288, 1986.
17. Boyd AW, Wawrijk SO, Burns GF, Fecondo JV: Intercellular adhesion molecule 1 (ICAM-1) has a central role in cell-cell contact-mediated immune mechanisms. Proc Natl Acad Sci USA 85:3095, 1988.
18. Goulmy E: Minor histocompatibility antigens in man and their role in transplantation. Transplant Rev 2:29, 1988.
19. Wawrijk SO, Novotny JR, Wicks IP, Wilkinson D, Maher D, Salvaris E, Welch K, Fecondo J, Boyd AW: The role of the LFA-1/ICAM-1 interaction in human leukocyte homing and adhesion. Immunol Rev 108:136, 1989.
20. Arnaout MA: Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 75:1037, 1990. [review]
21. Marijt WAF, Veenhof WFJ, Goulmy E, Willemze R, van Rood JJ, Falkenburg JHF: Minor histocompatibility antigens HA-1, -2 and -4, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell-cell contact. Blood 82:3778, 1993.
22. Voogt PJ, Fibbe WE, Marijt WA, Goulmy E, Veenhof WF, Hamilton M, Brand A, Zwaan FE, Willemze R, van Rood JJ, Falkenburg JHF: Rejection of bone-marrow graft by recipient-derived cytotoxic T lymphocytes against minor histocompatibility antigens. Lancet 335:131, 1990.
23. Barrett A, Jiang YZ: Immune responses to chronic myeloid leukaemia. Bone Marrow Transplant 9:305, 1992.
24. Higano CS, Rashkind WH, Singer JW: Use of alpha interferon for the treatment of relapse of chronic myelogenous leukemia in chronic phase after allogeneic bone marrow transplantation. Blood 6:1437, 1992.
25. Baron S, Tyring SK, Fleischmann WR, Coppenhaver DH, Niesel DW, Klimpel GR, Santon GJ, Hughes TK: The interferons: Mechanisms of action and clinical applications. JAMA 266:1375, 1991.
26. Borden EC: Interferons: Pleiotropic cellular modulators. Clin Immunol Immunopathol 62:S18, 1992.
27. Verma DS, Spitzer G, Gutterman JU, Zander AR, McCredie KB, Dicke KA: Human leukocyte interferon preparation blocks granulopoietic differentiation. Blood 54:1423, 1979.
28. 1+ chronic myelogenous leukemia cells maintained in long term marrow cultures: A functional and morphological analysis. J Biol Regul Homeost Agents 3:102, 1989.
29. Greenberg PL, Mosny SA: Cytotoxic effects of interferon in vitro on granulocytic progenitor cells. Cancer Res 37:1794, 1977.
30. Neumann HA, Fauser AA: Effect of interferon on pluripotent hematopoietic progenitors (CFU-GEMM) derived from human bone marrow. Exp Hematol 10:587, 1982.
31. Williams CKO, Svet-Moldavskaya I, Vilcek J, Ohnuma T, Holland JF: Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells. Oncology 38:356, 1981.
32. Broxmeyer HE, Lu L, Platzer E, Feit C, Juliano L, Rubin BY: Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol 131:1300, 1983.
33. Gresser I: The effect of interferon on the expression of surface antigens. In: J Vilcek, E de Maeyer (eds) Interferon. Volume 2: Interferons and the Immune System. Amsterdam: Elsevier, 113, 1964.